HOTH (Hoth Therapeutics) GF Score : 38/100 (As of Apr. 05, 2025)

View and export this data going back to 2019. Start your Free Trial

What is Hoth Therapeutics GF Score?

Hoth Therapeutics has the GF Score of 38, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 8/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 4/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Hoth Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Hoth Therapeutics's GF Score

For the Biotechnology subindustry, Hoth Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hoth Therapeutics's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hoth Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where Hoth Therapeutics's GF Score falls into.

Save Embed

;

Save Embed

;

Hoth Therapeutics (NAS:HOTH) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Hoth Therapeutics GF Score Related Terms

Thank you for viewing the detailed overview of Hoth Therapeutics's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Hoth Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hoth Therapeutics Inc (NAS:HOTH) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

590 Madison Avenue, 21st Floor, New York, NY, USA, 10022

Website

https://www.hoththerapeutics.com

Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

Executives

Robb Knie	director, officer: CEO and President	C/O INVENTERGY GLOBAL, INC., 900 EAST HAMILTON AVENUE SUITE 180, CAMPBELL CA 95008
Jeff Pavell	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Stefanie Johns	officer: Chief Scientific Officer	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Anthony Hayes	director	1796 SHADY LANE, COLUMBIA SC 29206
Wayne Linsley	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Graig Springer	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Spherix Inc	10 percent owner	725 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Vadim Mats	director	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Rice Kenneth L Jr	director	C/O 85 MAIN STREET, HOPKINTON MA 01748
David Sarnoff	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
David S. Briones	officer: Chief Financial Officer	C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Matthew D. Eitner	10 percent owner	44 BRAMS HILL DRIVE, MAHWAH NJ 07430
Kevin Jess Poor	10 percent owner	750 BEULAHS LANE, IDAHO FALLS ID 83401
James P. Ahern	10 percent owner	20 WEST 64TH STREET, APT 18RS, NEW YORK NY 10023